iGRO™ applies growth prediction algorithms, developed using clinical data in KIGS (the Pfizer International Growth Database) in clinical practice — supporting individualised GH treatments with personalised growth evaluations.1
The iGRO™ growth chart presents a child’s data as a growth curve in a single clear diagram. This shows how well a child is growing in comparison with a reference population and helps to monitor progress towards his or her target height throughout treatment.
The iGRO™ growth chart also displays yearly growth predictions.
iGRO™ growth chart with predictions
This helps you to compare the child’s actual growth with his or her predicted growth after each year of treatment, and to determine whether he or she is responding to GH as expected.
Discrepancies between observed and predicted growth responses give reason to search for causes, such as non-adherence to therapy and the presence of additional diseases, and may have therapeutic consequences, including GH dose modification or even termination of GH treatment.
Assessments of growth response can be used to guide further treatment decisions, and children with poor adherence to treatment can be identified. Possible causes for poor adherence can be investigated and additional support can be given to these patients, to help them fulfill their growth potential.
1 - Loftus J, Lindberg A, Aydin F, et al. Journal of Pediatric Endocrinology and Metabolism (2017);30:1019–1026.